teaser
NicOx S.A. today announced that additional clinical data for naproxcinod were presented yesterday at an oral session of the European Meeting on Hypertension, the annual congress of the European Society of Hypertension (ESH), which took place from June 18 to June 21 in Oslo, Norway. The abstract is available via the congress website (www.esh2010.com).
Naproxcinod is the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the relief of the signs and symptoms of osteoarthritis. It is currently under review by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
For more information, please click the link below:
NicOx
